StockNews.AI
VRTX
Forbes
201 days

FDA Approves Non-Opioid Painkiller With No Addiction Risk

1. FDA approved Vertex's Journavx for treating moderate to severe pain. 2. Journavx is a non-opioid with a price of $15.50 per pill. 3. Analysts estimate annual sales for Journavx could reach $1 billion. 4. Approval marks significant progress against opioid alternatives amid addiction crisis. 5. Vertex plans further studies for treating chronic pain with Journavx.

4m saved
Insight
Article

FAQ

Why Very Bullish?

The approval of Journavx enhances Vertex's product portfolio significantly, potentially increasing stock value.

How important is it?

The approval of a new drug can greatly influence company performance and stock prices.

Why Long Term?

Successful sales and expansion into chronic pain market could drive long-term revenue growth.

Related Companies

Related News